Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2/3 study of VLA2001 COVID-19 vaccine in the Netherlands
2022-000035-23Phase 2Completed
- Sponsor
- Valneva
- Start
- Feb 2022
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of VLA2001 in coronavirus disease 2019 (COVID-19), sponsored by Valneva. Primary endpoint: Primary immunogenicity endpoints. Started Feb 2022; status: completed.
02
Drugs
VLA2001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000035-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000035-23.